← Back to patent-cliff list
Zifogaptide
Tier C — Watch / tradeZifogaptide
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：GJA1
Brand：Granexin® Gel, Granexin
Indications (approved)：放射性皮炎, 瘢痕, Radiation injury, 烧伤, 糖尿病足溃疡, Trauma and injury, 静脉曲张溃疡
Regional status
US
Phase III
2018-11-21
EU
Discontinued
2018-11-21
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Zifogaptide?
Approved indications include: 放射性皮炎, 瘢痕, Radiation injury, 烧伤, 糖尿病足溃疡, Trauma and injury, 静脉曲张溃疡.
When does the Zifogaptide patent expire?
No public expiry year is available for Zifogaptide yet; this page updates once verified.
How do I get a quote for Zifogaptide intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-08